Reducing the Risk of Premature Ovarian Failure With LHRH Analog Administration With Chemotherapy in Breast Cancer
Halle Moore, MD, discusses a phase III trial that looked at reducing the risk of premature ovarian failure with LHRH analog administration with chemotherapy in women with breast cancer.
Clinical Pearls
Halle Moore, MD, medical oncologist, Cleveland Clinic, discusses aphase III trial presented at the 2014 ASCO Annual Meetingthat looked at reducing the risk of premature ovarian failure with LHRH analog administration with chemotherapy in women with breast cancer.
- The randomized phase III POEMS study looked at whether suppressing ovarian function during adjuvant or neoadjuvant chemotherapy could reduce the risk for long term ovarian failure in premenopausal women with ER-negative breast cancer.
- Patients were randomized to receive standard cyclophosphamide-containing chemotherapy with or without monthly LHRH analog goserelin.
- There was a significant reduction (about 70%) in the ovarian failure rate observed in the group treated with goserelin.
- At 2 years, women who received goserelin had better preserved ovarian function.
- There was a higher rate of achieving pregnancy and having successful births among women who received goserelin. There was no evidence that goserelin increased the risk of miscarriage, need for elective termination, or other adverse pregnancy events.
- The goserelin group had an improved disease-free survival as well as overall survival compared with the control group.
<<<
Jhaveri Compares Safety and Duration of Adjuvant CDK4/6 Inhibitors in HR+ Breast Cancer
December 22nd 2024During a Case-Based Roundtable® event, Komal Jhaveri, MD, FACP, discussed dosing and toxicity concerns with the approved CDK4/6 inhibitor regimens used in the adjuvant setting for patients with hormone receptor–positive breast cancer.
Read More
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
